Longitude Capital, a life science investment firm targeting mostly mid to late stage companies with about one quarter for early stage businesses, has made its first close for Longitude Venture Partners III, raising a total of $525 million, according to a company statement.
In a phone interview with Longitude Founder and Managing Director Marc Galletti, he said it would begin making investments from the newsest fund starting in the third quarter.
“We invest in exciting life science companies that can hit exciting milestones within three to five years of investment.”
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Galletti highlighted some of the technologies in which it has demonstrated an interest, such as ophthalmology, mitrovalve repair, food allergies, oncology and neurostimulation.
It helped start Aimmune, a publicly traded biotech business developing a treatment for peanut allergies affecting children that’s in phase three development. It also invested in Twelve, a medical device company that developed a transcatheter mitrovalve replacement device that Medtronic acquired last year.
Its more recent investments include participation in a $65 million Series A round for Aptinyx, a spinout of Naurex, which Allergan acquired in August last year.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
In April it invested in Kala Pharmaceuticals, a biotechnology company developing ophthalmology products such as a treatment for pain and inflammation following cataract surgery.
Photo: Flickr user Peasap
